CIK 0000875320 · Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 043039129
- Phone
- 6173416393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Lagarde Michel Director | Grant or award · Stock Option (Right to Buy) | +2,866 | 2,866 | ||
| 2026-05-01 | Garber Alan M Director | Grant or award | +472 | 7,344 | ||
| 2026-05-01 | Garber Alan M Director | Grant or award · Stock Option (Right to Buy) | +1,433 | 1,433 | ||
| 2026-05-01 | CARNEY LLOYD Director | Grant or award · Stock Option (Right to Buy) | +2,866 | 2,866 | ||
| 2026-05-01 | Bhatia Sangeeta N. Director | Grant or award 10b5-1 | +943 | 5,242 | ||
| 2026-04-15 | Upadhyay Suketu Director | Grant or award · Deferred Stock Units | +80.51 | $442.50 | $36K | 2,799.16 |
| 2026-04-15 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +107.35 | $442.50 | $48K | 15,671.87 |
| 2026-04-15 | Garber Alan M Director | Grant or award · Deferred Stock Units | +33.9 | $442.50 | $15K | 33.9 |
| 2026-04-01 | Liu Joy EVP and Chief Legal Officer | Sale 10b5-1 | −978 | $449.17 | $439K | 21,833 |
| 2026-03-27 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −2,329 | $450.95 | $1.1M | 33,076 |
| 2026-03-13 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −2,329 | $481.79 | $1.1M | 35,405 |
| 2026-03-11 | McKechnie Duncan EVP, Chief Commercial Officer | Sale 10b5-1 | −2,633 | $498.42 | $1.3M | 12,489 |
| 2026-03-04 | McKechnie Duncan EVP, Chief Commercial Officer | Sale 10b5-1 | −2,437 | $475.30 | $1.2M | 15,122 |
| 2026-03-02 | Liu Joy EVP and Chief Legal Officer | Sale 10b5-1 | −892 | $495.96 | $442K | 22,811 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −400 | $479.75 | $192K | 137,878 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −120 | $481.50 | $58K | 137,758 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −240 | $482.84 | $116K | 137,518 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −2,510 | $487.13 | $1.2M | 135,008 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −3,278 | $488.27 | $1.6M | 131,730 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −460 | $489.32 | $225K | 131,270 |
Page 3 of 10 · 182 trades